RxDoctor Payments DataLook up a doctor →

Rahul Argula

Critical Care Medicine · Charleston, SCNPI 1386841583

Payments from drug & device makers

$2,862,542in general payments, 2019–2025

Across 394 payments — averaging $7265.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.8M
  • United Therapeutics Corporation$769K
  • Novartis$142K
  • Janssen Research & Development, LLC$70K
  • Actelion Pharmaceuticals, Ltd$32K
  • Pfizer$30K
  • plus $28K from 5 others
$1,306in research payments, 2019–2025

Across 5 payments — averaging $261.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$1K
  • Insmed, Inc.$150

What the payments were for

  • Consulting fees$72,46539%
  • Speaking & faculty fees$85,39346%
  • Travel & lodging$21,85012%
  • Food & beverage$5,7963%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,862,542 in reported general payments places this provider in the 95th percentile of 93 critical care medicine providers in South Carolina.

See all critical care medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$94,375
Medicare patients
414
Services billed
1,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat315$4,217,496
Tyvaso DpiTreprostinil113$3,186,652
UptraviSelexipag89$2,249,674
Ambrisentan409$1,618,474
OpsumitMacitentan125$1,553,835
Orenitram ErTreprostinil Diolamine36$505,374
RemodulinTreprostinil Sodium38$376,731
OfevNintedanib Esylate22$287,507
WinrevairSotatercept-Csrk20$270,705
Tadalafil264$251,258
LetairisAmbrisentan16$193,233
JardianceEmpagliflozin78$62,759
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr72$36,439
Sildenafil Citrate94$27,067
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$26,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$14,893$4,217,496315 claims
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$11,963$3,803,509214 claims
United Therapeutics CorporationRemodulin$769,025$376,73138 claims
MerckWinrevair$1,791,303$270,70520 claims
PfizerEliquis$30,031$10,89817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 critical care medicine providers in South Carolina.

Other critical care medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →